NovaBridge Biosciences reported full-year 2025 results and set out a tighter, higher-stakes development agenda around two lead assets. In gastric cancer, phase 1b data for givastomig, a CLDN18.2 x 4-1BB bispecific, showed a 75% objective response rate and a 16.9-month median progression-free survival in first-line metastatic disease, with favorable tolerability. Following a recent Type B FDA meeting, the program was reported to be potentially eligible for an accelerated approval pathway in a defined first-line HER2-negative, CLDN18.2-positive, PD-L1-positive population, with a registrational study targeted as early as late 2026. In ophthalmology, VIS-101, a VEGF-A x Ang-2 inhibitor, delivered rapid vision gains, meaningful anatomic responses, and retreatment-free durability out to six months in a phase 2a wet AMD study; phase 2b is slated for the second half of 2026, with a global phase 3 in 2027. The company closed 2025 with $210.8 million in cash, guiding runway into 2028, and continued to build out a hub-and-spoke model, including its Visara ophthalmology “spoke” and additional antibody rights.
The strategy signals a company leaning into de-risked biology while accepting that the regulatory bar has risen. In frontline solid tumors, accelerated approvals have tightened around the quality of response and the speed and credibility of confirmatory evidence. In retinal disease, differentiation is now earned in durability, clinic workflow impact, and payer acceptance, not in mechanism novelty alone. NovaBridge is attempting to thread both needles with a bispecific that conditionally activates 4-1BB in the tumor microenvironment and an ophthalmology candidate designed to stretch dosing intervals without compromising vision outcomes.
For stakeholders, the timing matters. In gastric and gastroesophageal cancers, a biomarker-defined first-line segment could open quickly if confirmatory data are convincing and diagnostic pathways are ready. With roughly 180,000 first-line cases across the US, EU5, and Japan and an estimated 100,000-plus HER2-negative, CLDN18.2-positive patients, commercial scale hinges on CLDN18.2 testing adoption and clear PD-L1 cutoffs. Medical Affairs will need to drive assay standardization, tissue handling guidance, and clinician education to avoid friction at the point of care. In wet AMD, reducing injection frequency even modestly can reshape clinic capacity and patient adherence. Payers, however, will expect head-to-head or practical equivalence against entrenched agents before funding longer intervals at premium pricing.
Competitive dynamics are sharpening. The first wave of CLDN18.2-directed approaches, including late-stage monoclonal antibodies and emerging cell therapies, is defining the biomarker’s clinical role. A bispecific that safely amplifies T-cell costimulation at the tumor site could leapfrog single-target agents, but hepatotoxicity vigilance and clean combinability with chemo and PD-1 inhibitors will be scrutinized. In retina, Roche’s Vabysmo has already reset durability expectations and Regeneron’s high-dose aflibercept has extended dosing for many patients; any newcomer must prove either superior or reliably longer intervals supported by robust real-world data. Trial design choices, comparator selection, and early health economic modeling will heavily influence payer and retina practice adoption curves.
This update also slots neatly into broader industry currents: cross-border sourcing of de-risked assets, the rise of bispecifics that couple targeting with immune modulation, and capital-efficient platform structures that ringfence risk in asset-centric “spokes.” With runway projected to 2028, NovaBridge can reach key readouts but will likely need partnership capital or creative financings to traverse confirmatory studies and commercialization. The next 12 to 18 months will test whether the company can lock in a registrational path for givastomig with a fit-for-purpose companion diagnostic and generate comparative, practice-changing durability data for VIS-101. The strategic question now is whether NovaBridge can convert promising proof-of-concept into market-ready evidence fast enough to claim leadership before standards harden around rival CLDN18.2 regimens and long-interval retinal therapies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
